Abstract 270P
Background
Premenopausal women experience temporary ovarian function suppression (OFS) during the period of chemotherapy. In ER+ breast cancer, chemotherapy-induced temporary OFS may offer anti-estrogenic effect in addition to direct cytotoxic anti-tumor effect. It is unclear whether anti-estrogenic effect by temporary OFS during neo-adjuvant chemotherapy (NAC) enhance anti-tumor effect. Based on pathologic complete response (pCR) and complete cell-cycle arrest (CCCA), we compared pathologic response and outcomes between younger and older patients with ER+HER2- breast cancer treated with NAC.
Methods
Between 2007 January and 2021 June, we retrospectively identified 1,178 patients with ER+HER2- breast cancer who underwent NAC in the Gangnam Severance Hospital and the Asan Medical Center. We compared the pCR rate according to age under 45 and over 55 and investigated durations of NAC, clinical stage, and Ki-67. Pathologic complete response was defined as no invasive residual disease in both breast and axillae. In addition, we collected available Ki67 expression in surgical specimen after NAC. We defined low Ki67 with a cutoff of 2.7%. The recurrence-free survival was evaluated in patients with post-NAC Ki67.
Results
In all 1,178 patients, the pCR rate was 1.9% (22/1,178). The rate was 1.4% (8/552) in younger patients (age ≤45), whereas it was 3.6% (9/250) in older patients (age ≥55) (p= 0.063, Chi-square test). In 524 patients who received NAC consisting of anthracyclines and taxanes with a duration of NAC longer than 6 months, the pCR rate did not differ between the younger patients and the older (2.1%, 5/243 vs. 2.8%, 3/106; p= 0.703). In patients with post-NAC Ki67, the CCCA rates were 66.2% (307/464) in the younger and 39.8% (86/216) in the older, respectively (p<0.001). Survival analyses showed that, compared to patients with CCCA, those without CCCA experienced a significant decrease in RFS in both younger and older women.
Conclusions
While short-term OFS resulting from NAC led to a higher rate of CCCA in premenopausal women, younger women had notably poorer survival outcomes compared to older women. Among premenopausal women, achieving CCCA was associated with a slight improvement in treatment outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Gangnam Severance Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
273P - A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2
Presenter: Patrick Neven
Session: Poster session 02
274P - Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE study
Presenter: Joyce O'Shaughnessy
Session: Poster session 02
275P - Clinical and molecular impact of neoadjuvant chemotherapy (NACT) or endocrine therapy (NET) on hormone receptor positive (HR+)/HER2-negative (-) breast cancer (BC)
Presenter: Francesco Schettini
Session: Poster session 02
276P - Development and external validation of an artificial intelligence (AI)-based machine learning model (ML) for predicting pathological complete response (pCR) in hormone-receptor (HoR)-positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT)
Presenter: Luca Mastrantoni
Session: Poster session 02
277P - Fat body mass independently predicts incident vertebral fractures in breast cancer patients given adjuvant aromatase inhibitor therapy and denosumab
Presenter: Greta Schivardi
Session: Poster session 02
278P - Association between tamoxifen and endoxifen plasma levels and clotting proteins in patients with primary breast cancer
Presenter: Daan van Dorst
Session: Poster session 02
279P - Early changes in bone turnover biomarkers during AI therapy are related to loss bone mineral density, data of the B-ABLE cohort
Presenter: Tamara Martos Cardenas
Session: Poster session 02
280P - Adjuvant aromatase inhibitors in patients with PIK3CA mutation early breast cancer
Presenter: Kristin Reinhardt
Session: Poster session 02
282P - Analysis of Prosigna in hormone receptor-positive early-stage breast cancer cohort after 8 years of experience at a single institution
Presenter: DANIEL MORCHÓN ARAUJO
Session: Poster session 02